EDITORIAL
Published on 26 Jul 2024
Editorial: Multi-targeted tyrosine kinase inhibitors in the treatment of cancer and neurodegenerative disorders
doi 10.3389/fchem.2024.1460347
- 567 views
- Frontiers in Chemistry
- Chemical Biology
- Research Topics
- Multi-targeted Tyrosine Kinase Inhibitors in the Treatment of Cancer and Neurodegenerative Disorders
Multi-targeted Tyrosine Kinase Inhibitors in the Treatment of Cancer and Neurodegenerative Disorders
8,977
Total downloads
29k
Total views and downloads
Submit your idea
Select the journal/section where you want your idea to be submitted:
Articles
CASE REPORT
Published on 21 Jun 2024
Case report: successful response to bevacizumab combined with erlotinib for a novel FH gene mutation hereditary leiomyoma and renal cell carcinoma
doi 10.3389/fphar.2024.1373020
- 1,113 views
- 1 citation
CASE REPORT
Published on 18 Apr 2024
Rapid response to fifth-line brigatinib plus entrectinib in an ALK-rearranged lung adenocarcinoma with an acquired ETV6-NTRK3 fusion: a case report
doi 10.3389/fonc.2024.1339511
- 862 views
REVIEW
Published on 08 Jan 2024
Characterization of prevalent tyrosine kinase inhibitors and their challenges in glioblastoma treatment
doi 10.3389/fchem.2023.1325214
- 2,488 views
- 1 citation
ORIGINAL RESEARCH
Published on 21 Dec 2023
Sequential PET/CT and pathological biomarker crosstalk predict response to PD-1 blockers alone or combined with sunitinib in propensity score-matched cohorts of cancer of unknown primary treatment
doi 10.3389/fonc.2023.1191611
- 1,198 views
CASE REPORT
Published on 27 Nov 2023
Aumolertinib: effective treatment for asymptomatic pulmonary giant cell carcinoma with EGFR L858R mutation - a case report
doi 10.3389/fonc.2023.1279045
- 879 views
- 2 citations
SYSTEMATIC REVIEW
Published on 07 Sep 2023
Comparative safety of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis
doi 10.3389/fphar.2023.1223929
- 3,105 views
- 7 citations
CASE REPORT
Published on 10 Aug 2023
Case Report: Molecular and microenvironment change upon midostaurin treatment in mast cell leukemia at single-cell level
doi 10.3389/fimmu.2023.1210909
- 1,925 views
- 1 citation
CLINICAL TRIAL
Published on 21 Jul 2023
Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma
doi 10.3389/fimmu.2023.1188308
- 2,279 views
- 8 citations
ORIGINAL RESEARCH
Published on 07 Jul 2023
Real-world treatment patterns, discontinuation and clinical outcomes in patients with B-cell lymphoproliferative diseases treated with BTK inhibitors in China
doi 10.3389/fimmu.2023.1184395
- 2,301 views
- 2 citations
REVIEW
Published on 31 May 2023
The multikinase inhibitor axitinib in the treatment of advanced hepatocellular carcinoma: the current clinical applications and the molecular mechanisms
doi 10.3389/fimmu.2023.1163967
- 2,808 views
- 10 citations
ORIGINAL RESEARCH
Published on 12 Apr 2023
A single-arm phase II clinical trial of anlotinib combined with chemotherapy for the treatment of metastatic triple-negative breast cancer
doi 10.3389/fonc.2023.1122294
- 1,543 views
- 4 citations
Published in
Frontiers in Chemistry
- Chemical Biology
- Medicinal and Pharmaceutical Chemistry
Participating Journals
Frontiers in Oncology
- 3.5 impact factor
- 6.2 citescore
Frontiers in Pharmacology
- 4.4 impact factor
- 7.8 citescore
Impact
- 29kTopic views
- 19kArticle views
- 8,977Article downloads